{"id":"W1990925084","doi":"10.1016/s1473-3099(13)70257-3","title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":372,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Raltegravir; Dolutegravir; Medicine; Emtricitabine; Tolerability; Abacavir; Lamivudine; Population; Internal medicine; Clinical trial; Integrase inhibitor; Human immunodeficiency virus (HIV); Viral load; Adverse effect; Antiretroviral therapy; Virology; Virus; Chronic hepatitis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003479032,0.003593256,0.005940785,0.0006638144,0.0006355709,0.00173063,0.001949254,0.003804122,0.01399705],"category_scores_gemma":[0.003848656,0.001596033,0.003912409,0.0005064805,0.002121557,0.002775961,0.0008293004,0.004816584,0.003040355],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007903979,"about_ca_system_score_gemma":0.0008619599,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001114439,"about_ca_topic_score_gemma":0.001845366,"domain_scores_codex":[0.9984401,0.0009329535,0.00009492526,0.0002727567,0.00008426329,0.0001750107],"domain_scores_gemma":[0.997749,0.0008446721,0.0004709049,0.0003453704,0.00009788258,0.000492105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.993193,0.001390956,0.0001015146,0.0003149868,0.0004128563,0.00001753022,0.00003100677,0.00009933424,0.0009849892,0.00004113909,0.0002556842,0.003157117],"study_design_scores_gemma":[0.9872722,0.01173515,0.0003509691,0.00001670556,0.0001937822,0.00001253125,0.0000112679,0.00009558179,0.00009975064,0.00007753015,0.0001236136,0.0000108342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822918,0.005825411,0.001173333,0.001180567,0.001242466,0.002866844,0.002615732,0.0003292774,0.002474675],"genre_scores_gemma":[0.971963,0.003989247,0.003418502,0.001810383,0.001333561,0.004768318,0.002028208,0.0001346764,0.01055421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01399705,"threshold_uncertainty_score":0.04682481,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03039458746160299,"score_gpt":0.2889750520106316,"score_spread":0.2585804645490286,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}